Medical Device News Magazine

National Launch of the ShurFit 2C Interbody Systems Featuring Titanium Plasma Spray and Hydroxyapatite Coating

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

ShurFit 2C Interbody Systems: Precision Spine, Inc. has launched nationally the ShurFit ACIF 2C Anterior Cervical, TLIF 2C, and TPLIF 2C Posterior Interbody Systems, which is made from medical grade polyetheretherketone (Peek Optima, LT1) and coated with both commercially pure Titanium (Ti) and Hydroxyapatite (HA).

“The ShurFit 2C Interbody System’s distinguishing feature is its unique coating of both Titanium and Hydroxyapatite that helps increase durability and makes enhanced fixation possible while the process of biologic fusion takes place,” said Stephen D. Cook, Ph.D., Executive Director and Founder of the Fellowship of Orthopaedic Researchers, who was instrumental in the design and development of the device with Precision Spine engineers.

The ShurFit 2C coating technology combines a high-strength PEEK core with a unique, dual layer of coatings applied directly to the endplate surfaces. A biocompatible plasma-sprayed CP Titanium coating, with an outer layer of osteoconductive Hydroxyapatite, provides an optimal environment for osseointegration. The dual coating promotes rapid bone formation, which offers implant stability, less potential for implant migration, and the formation of a stable fusion mass while strategically placed tantalum markers facilitate radiographic implant positioning.

“The ShurFit ACIF 2C Systems are an important addition to our growing portfolio of devices,” said Chris DeNicola, Chief Operating Officer of Precision Spine, “and is further evidence of Precision Spine’s continuing commitment to work with surgeons in the design and commercialization of advanced products that utilize the latest technology to help bring greater versatility, efficiency, and cost-effectiveness to the OR.”

The ShurFit ACIF 2C system is indicated for use in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine at one disc level and consists of implants with various heights to accommodate individual patient anatomy and graft material size. It is implanted from the anterior approach at the C3 to C-7 disc levels and is designed to be packed with autogenous bone graft to help facilitate fusion while providing mechanical support to the implanted level until biologic fusion is achieved.

The ShurFit TLIF 2C and TPLIF 2C Interbody Fusion Devices are indicated for intervertebral body fusion of the spine in skeletally mature patients. The device system is designed for use with autograft to facilitate fusion. One device is used per intervertebral space for the TLIF 2C and TPLIF 2C system. Two devices are used per intervertebral space for the PLIF 2C system.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”